Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

Successful completion of technical transfer for DermaPure manufacturing at CellRight Facility

First product sales from inhouse manufacturing

Leeds, 24 April 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company is pleased to announce that, following the successful completion of the manufacturing technical transfer, it has commenced sales of DermaPure products processed at the CellRight Technologies ("CellRight") facility in San Antonio, Texas.

The completion of the transfer of DermaPure, ahead of schedule, brings a number of benefits to the Group including: 

· Expand manufacturing capabilities to meet increasing demands from Global sales and distribution partners

· Improves supply chain production efficiency, and product life cycle management

· Process enhancements increase DermaPure's shelf life from two to three years

· Inhouse manufacturing will facilitate the augmentation of its product portfolio

Commercialised under the recently rebranded TRX BioSurgery division, DermaPure, is being utilised in an increased number of clinical applications including acute and chronic wound care, orthopaedic trauma, dental, and following the exclusive distribution agreement with ARMS medical, urogynaecology and urology. 

Steve Couldwell, CEO, Tissue Regenix Group commented: "We are extremely encouraged by the continued progress integrating CellRight into the Tissue Regenix Group. Completing the transfer of DermaPure manufacturing to our CellRight facility was achieved, ahead of schedule, and incorporated significant process improvements which is a testament to the CellRight team. This is an important strategic milestone in the Group's long-term commercial strategy and I am pleased that the operational synergies are developing as expected. As a result we now have greater flexibility to explore new product opportunities to meet patient demand, expanding the markets we operate in with a reduced manufacturing risk profile."

For more Information:

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.